SG11201504372UA - A method of purifying therapeutic proteins - Google Patents
A method of purifying therapeutic proteinsInfo
- Publication number
- SG11201504372UA SG11201504372UA SG11201504372UA SG11201504372UA SG11201504372UA SG 11201504372U A SG11201504372U A SG 11201504372UA SG 11201504372U A SG11201504372U A SG 11201504372UA SG 11201504372U A SG11201504372U A SG 11201504372UA SG 11201504372U A SG11201504372U A SG 11201504372UA
- Authority
- SG
- Singapore
- Prior art keywords
- therapeutic proteins
- purifying therapeutic
- purifying
- proteins
- therapeutic
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261733761P | 2012-12-05 | 2012-12-05 | |
EP13153898 | 2013-02-04 | ||
US13/803,740 US20140154233A1 (en) | 2012-12-05 | 2013-03-14 | Method of purifying therapeutic proteins |
AU2013203357A AU2013203357B2 (en) | 2012-12-05 | 2013-04-10 | A method of purifying therapeutic proteins |
PCT/AU2013/001414 WO2014085861A1 (en) | 2012-12-05 | 2013-12-05 | A method of purifying therapeutic proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201504372UA true SG11201504372UA (en) | 2015-07-30 |
Family
ID=47630209
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201704484QA SG10201704484QA (en) | 2012-12-05 | 2013-12-05 | A method of purifying therapeutic proteins |
SG11201504372UA SG11201504372UA (en) | 2012-12-05 | 2013-12-05 | A method of purifying therapeutic proteins |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201704484QA SG10201704484QA (en) | 2012-12-05 | 2013-12-05 | A method of purifying therapeutic proteins |
Country Status (13)
Country | Link |
---|---|
US (5) | US20140154233A1 (ja) |
EP (2) | EP3483173A1 (ja) |
JP (2) | JP6411360B2 (ja) |
KR (2) | KR102240978B1 (ja) |
CN (2) | CN104981476B (ja) |
AU (2) | AU2013203357B2 (ja) |
BR (1) | BR112015012854B1 (ja) |
CA (2) | CA3185085A1 (ja) |
HK (1) | HK1214833A1 (ja) |
PL (1) | PL2928905T3 (ja) |
RU (1) | RU2685956C2 (ja) |
SG (2) | SG10201704484QA (ja) |
WO (1) | WO2014085861A1 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013135684A1 (en) | 2012-03-13 | 2013-09-19 | Octapharma Ag | Improved process for production of fibrinogen and fibrinogen produced thereby |
US20140154233A1 (en) | 2012-12-05 | 2014-06-05 | Csl Limited | Method of purifying therapeutic proteins |
US10188965B2 (en) | 2012-12-05 | 2019-01-29 | Csl Behring Gmbh | Hydrophobic charge induction chromatographic depletion of a protein from a solution |
GB201506113D0 (en) | 2015-04-10 | 2015-05-27 | Ge Healthcare Bio Sciences Ab | Method for chromatography |
GB201506117D0 (en) | 2015-04-10 | 2015-05-27 | Ge Healthcare Bio Sciences Ab | Method for chromatography |
US20180369346A1 (en) * | 2016-01-07 | 2018-12-27 | Eio Biomedical Ltd. | Methods, compositions and kits for reducing tissue adhesions |
WO2018042438A2 (en) * | 2016-09-01 | 2018-03-08 | Plas-Free Ltd | Human blood-derived products having decreased fibrinolytic activity and uses thereof in hemostatic disorders |
BR112020002234A2 (pt) * | 2017-08-23 | 2020-07-28 | Csl Behring Gmbh | método para a filtragem de virus do fator von willebrand |
CN109078628B (zh) * | 2018-08-27 | 2021-06-11 | 西北大学 | 一种以苄胺为配基的高效疏水相互作用色谱介质、制备方法及其在蛋白质复性与纯化的应用 |
FR3090321B1 (fr) * | 2018-12-21 | 2023-07-14 | Lab Francais Du Fractionnement | Procédé de filtration du fibrinogène |
US20220380439A1 (en) | 2020-11-09 | 2022-12-01 | Takeda Pharmaceutical Company Limited | Purification of fviii from plasma using silicon oxide adsorption |
JP2024513983A (ja) | 2021-04-13 | 2024-03-27 | グリフォルス・ワールドワイド・オペレーションズ・リミテッド | 第viii因子または第viii因子/フォン・ヴィレブランド因子複合体を含む液体組成物 |
CN115181178B (zh) * | 2021-09-04 | 2024-04-26 | 广东双林生物制药有限公司 | 一种从冷沉淀中制备人纤维蛋白原的方法 |
US20230210958A1 (en) | 2021-12-30 | 2023-07-06 | Baxter International Inc. | Fibrinogen and thrombin solutions for a fibrin sealant and fibrin sealant kit |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4764369A (en) | 1983-07-14 | 1988-08-16 | New York Blood Center Inc. | Undenatured virus-free biologically active protein derivatives |
US4540573A (en) | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
FR2632309B1 (fr) * | 1988-06-07 | 1990-08-24 | Lille Transfusion Sanguine | Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus |
WO1993005067A1 (en) * | 1991-09-05 | 1993-03-18 | Baxter International, Inc. | Topical fibrinogen complex |
FR2686883B1 (fr) * | 1992-02-04 | 1994-05-13 | Aquitaine Develop Transf Sanguin | Procede de fabrication de fibrinogene de tres haute purete, fibrinogene de tres haute purete obtenu ainsi qu'une composition pharmaceutique le contenant. |
ES2139227T5 (es) | 1994-07-14 | 2011-05-04 | Caf-Dcf Département Central De Fractionnement De La Croix Rouge S.C.R.L. | Concentrado de fibrinógeno obtenido de plasma sanguíneo, procedimiento e instalación para su preparación. |
WO1996007728A1 (en) * | 1994-09-02 | 1996-03-14 | New York Blood Center, Inc. | Production and secretion of recombinant fibrinogen by yeast |
US6037457A (en) * | 1997-01-31 | 2000-03-14 | The University Of North Carolina At Chapel Hill | Method for recombinant fibrinogen production |
FR2772381B1 (fr) | 1997-12-15 | 2001-06-08 | Lab Francais Du Fractionnement | Procede de preparation par filtration d'une solution de facteur viii securisee viralement |
AU6104799A (en) * | 1998-09-24 | 2000-04-10 | Ppl Therapeutics (Scotland) Limited | Purification of fibrinogen from fluids by precipitation and hydrophoic chromatography |
AU5441101A (en) | 1999-12-23 | 2001-07-03 | Rodger H. Rast | System and method for providing individualized dosing |
NZ518692A (en) | 1999-12-23 | 2004-08-27 | Csl Ltd | Purified fibrinogen free of destabilising levels of plasminogen and other proteases obtained from a Fraction I paste |
WO2002095019A1 (en) * | 2001-05-21 | 2002-11-28 | Omrix Biopharmaceuticals S.A. | Removal of plasmin(ogen) from protein solutions |
AUPR638801A0 (en) | 2001-07-13 | 2001-08-09 | Life Therapeutics Limited | Factor viii separation |
EP1450829A1 (en) * | 2001-10-03 | 2004-09-01 | Christopher J. Woolverton | Storage-stable fibrinogen solutions |
AU2002340776A1 (en) * | 2001-10-30 | 2003-05-12 | Novozymes A/S | High throughput isolation of proteins by charge induction chromatography |
DE10211632A1 (de) | 2002-03-15 | 2003-10-09 | Aventis Behring Gmbh | Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration |
JP4319979B2 (ja) * | 2002-04-26 | 2009-08-26 | ジェネンテック・インコーポレーテッド | タンパク質の非アフィニティ精製 |
GB0216001D0 (en) | 2002-07-10 | 2002-08-21 | Nat Blood Authority | Process and composition |
DE10261126A1 (de) | 2002-08-13 | 2004-03-04 | Aventis Behring Gmbh | Lagerungsstabile, flüssige Fibrinogen-Formulierung |
DE10246125A1 (de) | 2002-10-01 | 2004-04-15 | Aventis Behring Gmbh | Konzentrat eines Faktor VIII:C-haltigen von-Willebrand-Faktors und das dazu gehörige Verfahren |
ES2214967B1 (es) | 2003-03-06 | 2005-06-16 | Probitas Pharma, S.A | Procedimiento para la eliminacion de virus en soluciones de fibrinogeno y fibrinogeno obtenido por dicho procedimiento. |
DE102004009400A1 (de) * | 2004-02-24 | 2005-09-08 | Zlb Behring Gmbh | Fibrinogen Reinigung |
US20070142629A1 (en) * | 2004-06-16 | 2007-06-21 | Ciphergen Biosystems, Inc. | Multichemistry fractionation |
ATE546520T1 (de) * | 2007-01-04 | 2012-03-15 | Crucell Holland Bv | Faktor-xi-reinigung |
AU2008274195B2 (en) | 2007-07-11 | 2013-09-05 | Novo Nordisk A/S | Purification of factor VIII using a mixed-mode or multimodal resin |
EP2027875A1 (en) * | 2007-08-23 | 2009-02-25 | Octapharma AG | A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC) |
FR2920429B1 (fr) * | 2007-08-30 | 2012-10-05 | Lfb Biotechnologies | Procede de purification du facteur viii et du facteur von willebrand |
KR20100103595A (ko) | 2008-01-18 | 2010-09-27 | 에프. 호프만-라 로슈 아게 | 비-글라이코실화된 단백질의 정제 |
KR101700722B1 (ko) * | 2008-06-24 | 2017-01-31 | 옥타파마 아게 | 응고 인자 viii을 정제하는 방법 |
US20130011382A1 (en) * | 2010-01-08 | 2013-01-10 | Profibrix Bv | Fibrinogen Preparations Enriched In Fibrinogen With An Extended Alpha Chain |
CN103328503B (zh) | 2010-09-20 | 2016-08-24 | 欧克塔医药公司 | 纤维蛋白原生产方法 |
EP2649087A1 (en) * | 2010-12-08 | 2013-10-16 | Amgen Inc. | Ion exchange chromatography in the presence of an amino acid |
WO2013135684A1 (en) | 2012-03-13 | 2013-09-19 | Octapharma Ag | Improved process for production of fibrinogen and fibrinogen produced thereby |
US20140154233A1 (en) | 2012-12-05 | 2014-06-05 | Csl Limited | Method of purifying therapeutic proteins |
-
2013
- 2013-03-14 US US13/803,740 patent/US20140154233A1/en not_active Abandoned
- 2013-04-10 AU AU2013203357A patent/AU2013203357B2/en active Active
- 2013-12-05 KR KR1020157017824A patent/KR102240978B1/ko active IP Right Grant
- 2013-12-05 JP JP2015545601A patent/JP6411360B2/ja active Active
- 2013-12-05 CN CN201380063945.1A patent/CN104981476B/zh active Active
- 2013-12-05 CA CA3185085A patent/CA3185085A1/en active Pending
- 2013-12-05 AU AU2013354899A patent/AU2013354899B2/en active Active
- 2013-12-05 KR KR1020217010484A patent/KR102403847B1/ko active IP Right Grant
- 2013-12-05 RU RU2015126551A patent/RU2685956C2/ru active
- 2013-12-05 CN CN201811091750.9A patent/CN109125714B/zh active Active
- 2013-12-05 WO PCT/AU2013/001414 patent/WO2014085861A1/en active Application Filing
- 2013-12-05 SG SG10201704484QA patent/SG10201704484QA/en unknown
- 2013-12-05 SG SG11201504372UA patent/SG11201504372UA/en unknown
- 2013-12-05 BR BR112015012854-8A patent/BR112015012854B1/pt active IP Right Grant
- 2013-12-05 CA CA2893373A patent/CA2893373A1/en not_active Abandoned
- 2013-12-05 EP EP18207150.6A patent/EP3483173A1/en active Pending
- 2013-12-05 PL PL13861334T patent/PL2928905T3/pl unknown
- 2013-12-05 EP EP13861334.4A patent/EP2928905B1/en active Active
-
2014
- 2014-11-06 US US14/535,085 patent/US9598461B2/en active Active
-
2016
- 2016-03-10 HK HK16102793.7A patent/HK1214833A1/zh unknown
-
2017
- 2017-02-03 US US15/424,072 patent/US20170143805A1/en not_active Abandoned
-
2018
- 2018-09-25 JP JP2018178301A patent/JP6836562B2/ja active Active
- 2018-12-10 US US16/214,519 patent/US11426680B2/en active Active
-
2021
- 2021-03-01 US US17/188,173 patent/US20210283530A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1214833A1 (zh) | 種純化治療性蛋白質的方法 | |
HRP20181357T1 (hr) | Novi postupci pročišćavanja proteina | |
HK1219964A1 (zh) | 治療性蛋白藥物物質的整合連續製造 | |
EP2883882A4 (en) | PROCESS FOR PURIFYING PROTEINS | |
GB201217772D0 (en) | Sequencing method | |
EP2720719A4 (en) | METHOD FOR SELECTION OF THERAPEUTIC INDICATIONS | |
HK1192587A1 (zh) | 治療性融合蛋白 | |
EP2773754A4 (en) | Methods of Treatment | |
GB201110095D0 (en) | Method of treatment | |
HK1212995A1 (zh) | 種純化蛋白質的方法 | |
EP2727930A4 (en) | PROCESS FOR CLEANING PROTEINS | |
ZA201502595B (en) | Therapeutic methods | |
HK1216504A1 (zh) | 疾病的治療方法 | |
GB201209082D0 (en) | Purification method | |
HK1211789A1 (en) | Plants for production of therapeutic proteins | |
EP2762486A4 (en) | PROCESS FOR PURIFYING PROTEIN | |
SG10201911709RA (en) | A method of purifying therapeutic proteins | |
EP2791324A4 (en) | PROCESSING METHOD | |
GB201215435D0 (en) | Sequencing method | |
GB201217173D0 (en) | Therapeutic method | |
EP2814499A4 (en) | PURIFICATION PROCESS | |
GB201221032D0 (en) | Method of treatment | |
GB201207894D0 (en) | Method of treatment | |
GB201111530D0 (en) | Method of treatment | |
GB201109509D0 (en) | Method of treatment |